Table 2.
Comparison between BCL2-CLLS and BCL3-CLLS
| Patients | BCL2-CLLS n=75 | BCL3-CLLS n=29 | p |
|---|---|---|---|
| Morphology CLL | 47 (63%) | 9 (31%) | <0.005 |
| Atypical CLL | 28 (37%) | 20 (69%) | |
| Gender ratio: M/F | 57/18 | 18/11 | 0.22 |
| Age at diagnosis | 66 [32-83] | 62 [39-79] | 0.14 |
| Binet stage | 63A/4B/1C | 16A/5B/4C | 0.37 |
| Splenomegaly | 3/61 (5%) | 13/28 (46%) | <0.0001 |
| Lymphocytes count x109/l (median, range) | 14.6 [5.4-106.2] | 24.4 [5.5-514] | <0.008 |
| Matutes score | |||
| ≥4 | 57/68(84%) | 5/20 (25%) | <0.001 |
| =3 | 7/68 (10%) | 5/20 (25%) | |
| <3 | 4/68 (6%) | 10/20 (50%) | |
| CD5 positive | 69/73 (94%) | 27/29 (93%) | 0.99 |
| CD38 negative | 45/64 (70%) | 1/5 (20%) | <0.04 |
| Karyotype/ FISH | |||
| Variant translocation | 13/75* (17%) | 0/29 | <0.02 |
| Complex (≥3 abnormalities) | 15/74 (20%) | 13/28 (46%) | <0.02 |
| Single translocation | 25/74 (34%) | 1/28 (4%) | <0.002 |
| Trisomy 12 | 33/75 (44%) | 20/29 (69%) | <0.03 |
| 13q14 deletion | 32/68(47%) | 4/27 (15%) | <0.005 |
| TP53 deletion | 1/72 (1%) | 4/23 (17%) | <0.02 |
| ATM deletion | 0/72 (0%) | 2/24 (8%) | 0.06 |
| 6q deletion | 0/59 (0%) | 5/25 (20%) | <0.002 |
| Mutated cases | 33/41 (80%) | 2/20 (10%) | <0.0001 |
| IGHV4-39 | 1/41 (2%) | 5/20 (25%) | <0.02 |
| Treated cases | 35/64 (55%) | 21/28 (75%) | 0.1 |
| TFS interval (median +/-SEB) | 48 +/-12 months | 1.2 +/-1 months | <0.0001 |
CLL: chronic Iymphocytic leukemia, standard error. TFS: treatment-free survival.
*
: 11t(18;22), 2 t(2;18). M: male. F: female. ¤SE: standed error.